Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTx-024 in ER+ Metastatic Breast Cancer
NCT01616758Phase 2Terminated
- Sponsor
- GTx
- Start
- Apr 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enobosarm in breast cancer, sponsored by GTx. Primary endpoint: Percentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast Cancer at 6 months. Started Apr 2013; status: terminated.
02
Drugs
enobosarm
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01616758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616758.